Syngene International Limited
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Operating margin of 27.5% exceeds Healthcare median (24.8%)
Concerns1
- Operating margin declining for 3 consecutive years (29.0% β 28.0% β 27.0%)
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ3.37 K Cr | β | βΉ468.00 Cr | β | β | 10.1% | 5.3% | 0.4% |
| Mar 2024 | βΉ3.20 K Cr | β | βΉ466.00 Cr | β | β | 11.1% | 0.3% | -1.5% |
| Mar 2023 | βΉ3.19 K Cr | β | βΉ473.00 Cr | β | β | 13.1% | 22.8% | 20.1% |
| Mar 2022 | βΉ2.60 K Cr | β | βΉ394.00 Cr | β | β | 12.0% | 19.4% | -2.5% |
| Mar 2021 | βΉ2.18 K Cr | β | βΉ404.00 Cr | β | β | 14.3% | 8.3% | -1.9% |
| Mar 2020 | βΉ2.01 K Cr | β | βΉ412.00 Cr | β | β | 19.0% | 10.2% | 24.5% |
| Mar 2019 | βΉ1.83 K Cr | β | βΉ331.00 Cr | β | β | 16.8% | 28.3% | 8.5% |
| Mar 2018 | βΉ1.42 K Cr | β | βΉ305.00 Cr | β | β | 17.7% | 18.5% | 6.3% |
| Mar 2017 | βΉ1.20 K Cr | β | βΉ287.00 Cr | β | β | 20.3% | 8.5% | 19.1% |
| Mar 2016 | βΉ1.11 K Cr | β | βΉ241.00 Cr | β | β | 23.5% | 28.7% | 37.7% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 3,455 |
| Total Expenses | 2,548 |
| EBIT / Operating Profit | 906 |
| OPM % | 26% |
| Other Income | 67 |
| Finance Costs | 30 |
| Depreciation & Amortisation | 377 |
| Profit Before Tax | 567 |
| Tax % | - |
| Net Profit / PAT | 438 |
| EPS (βΉ) | 10.87 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Syngene International Limitedthis co. | βΉ25.38 K Cr | βΉ3.37 K Cr | 58.00 | 5.48 | 26.54 | 5.3% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |